Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials
- PMID: 19006546
- PMCID: PMC2668090
- DOI: 10.1111/j.1365-2125.2008.03308.x
Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials
Abstract
Aims: To assess the effect of statins on a range of health outcomes.
Methods: We undertook a population-based cohort study to assess the effect of statins on a range of health outcomes using a propensity score-based method to control for differences between people prescribed and not prescribed statins. We validated our design by comparing our results for vascular outcomes with the effects established in large randomized trials. The study was based on the United Kingdom Health Improvement Network database that includes the computerized medical records of over four and a half million patients.
Results: People who initiated treatment with a statin (n = 129,288) were compared with a matched sample of 600,241 people who did not initiate treatment, with a median follow-up period of 4.4 years. Statin use was not associated with an effect on a wide range of outcomes, including infections, fractures, venous thromboembolism, gastrointestinal haemorrhage, or on specific eye, neurological or autoimmune diseases. A protective effect against dementia was observed (hazard ratio 0.80, 99% confidence interval 0.68, 0.95). There was no effect on the risk of cancer even after > or =8 years of follow-up. The effect sizes for statins on vascular end-points and mortality were comparable to those observed in large randomized trials, suggesting bias and confounding had been well controlled for.
Conclusions: We found little evidence to support wide-ranging effects of statins on health outcomes beyond their established beneficial effect on vascular disease.
References
-
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
-
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78. Cholesterol Treatment Trialists’ (CTT) Collaborators. - PubMed
-
- IMS. 2006. [last accessed 28 March 2008]. Leading Therapy Classes by Global Pharmaceutical Sales. Available at http://www.imshealth.com/ims/portal/front/articleC/0,2777,6025_80528184_....
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
